ArticleOncotarget2017

Discovery and characterization of a novel irreversible EGFR mutants selective and potent kinase inhibitor CHMFL-EGFR-26 with a distinct binding mode.

Chen Hu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.